ReviewDrug delivery2017
Mesoporous carbon nanomaterials in drug delivery and biomedical application.
Review in Drug delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 184 citations in OpenAlex.
- Baicalin: A comprehensive review of its molecular mechanisms and pharmacological activities.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Nanomaterial-Based Photothermal Therapy for Inflammatory Diseases: Intervention Strategies, Synergistic Effects, and Future Challenges.International journal of nanomedicine · 2026Review
- Comprehensive Review of Mesoporous Carbon and Mesoporous Silica in Poorly Soluble Drug Delivery: Insights into Drug Loading, Dissolution, Stability, and Pharmacological Performance.International journal of nanomedicine · 2026Review
- Ionic liquids self-assembled micelles for transdermal delivery: characterization, functions and applications.International journal of pharmaceutics: X · 2025Review
- Recent trends in mesoporous carbon-based nanoplatforms for biomedical application.Journal of pharmaceutical analysis · 2025Review
- Carbon nanotubes/ordered mesoporous carbon/chitosan nanocomposite as a promising carrier for everolimus targeted delivery toward lung cancer cells.Journal of materials science. Materials in medicine · 2025Article
- Biochar Utilization in Antimicrobial, Anticancer, and Biosensing Applications: A Review.Biomolecules · 2025Review
- Tau-targeting nanoparticles for treatment of Alzheimer's disease.Exploration (Beijing, China) · 2025Review
- Biomedical Aerogels in Wound Healing: Therapeutic Strategies and Translational Insights.Biomaterials research · 2025Review
- Recent Advances in Targeted Nanocomposite-based Therapeutics for Cancer Therapy.Current drug research reviews · 2025Review
- Recent Trends in Biomedical Applications of CuInternational journal of nanomedicine · 2025Review
- Transepithelial transport of nanoparticles in oral drug delivery: From the perspective of surface and holistic property modulation.Acta pharmaceutica Sinica. B · 2024Review
- In Vitro Assessment ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Surface Modification of Mesoporous Silica Nanoparticles for Application in Targeted Delivery Systems of Antitumour Drugs.Polymers · 2024Review
- Mesoporous Carbons and Highly Cross-Linking Polymers for Removal of Cationic Dyes from Aqueous Solutions-Studies on Adsorption Equilibrium and Kinetics.Materials (Basel, Switzerland) · 2024Article
- MgClBiological trace element research · 2023Article
- MRI Directed Magnevist Effective to Study Toxicity of Gd-Doped Mesoporous Carbon Nanoparticles in Mice Model.International journal of nanomedicine · 2023Article
- Sorafenib-Loaded PLGA Carriers for Enhanced Drug Delivery and Cellular Uptake in Liver Cancer Cells.International journal of nanomedicine · 2023Article
- Insight into Potential Biomedical Application of Mesoporous Materials.Pharmaceutics · 2022Review
- A magnetic antibody-conjugated nano-system for selective delivery of Ca(OH)Communications biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent development of nano-technology provides highly efficient and versatile treatment methods to achieve better therapeutic efficacy and lower side effects of malignant cancer. The exploration of drug delivery systems (DDSs) based on nano-material shows great promise in translating nano-technology to clinical use to benefit patients. As an emerging inorganic nanomaterial, mesoporous carbon nanomaterials (MCNs) possess both the mesoporous structure and the carbonaceous composition, endowing them with superior nature compared with mesoporous silica nanomaterials and other carbon-based materials, such as carbon nanotube, graphene and fullerene. In this review, we highlighted the cutting-edge progress of carbon nanomaterials as drug delivery systems (DDSs), including immediate/sustained drug delivery systems and controlled/targeted drug delivery systems. In addition, several representative biomedical applications of mesoporous carbon such as (1) photo-chemo synergistic therapy; (2) delivery of therapeutic biomolecule and (3) in vivo bioimaging are discussed and integrated. Finally, potential challenges and outlook for future development of mesoporous carbon in biomedical fields have been discussed in detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.